RecruitingNCT04890067
Observational Study in Localized Osteosarcoma
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italian Sarcoma Group
- Intervention
- Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)(other)
- Enrollment
- 120 target
- Eligibility
- 40 years · All sexes
- Timeline
- 2021 – 2026
Study locations (16)
- Centro di Riferimento Oncologico - Unit of Medical Oncology, Aviano, Pordenone, Italy
- Sandra Aliberti, Candiolo, Torino, Italy
- IRCCS materno infantile Burlo Garofolo, Trieste, T, Italy
- Azienda Ospedaliero Universitaria Consorziale Policlinico - Bari, Bari, Italy
- IRCCS Istituto ortopedico Rizzoli, Bologna, Italy
- A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna, Bologna, Italy
- AUO Policnico G. Rodolico San Marco, Catania, Italy
- A.O. Universitaria Meyer, Florence, Italy
- Istituto Giannina Gaslini, Genova, Italy
- Fondazione IRCCS INT Milano SC Pediatria Oncologica, Milan, Italy
- FONDAZIONE IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Azienda Ospedaliera di Padova UOC Oncoematologia Pediatrica, Padova, Italy
- ARNAS P. O. "Civico e Benfratelli", Palermo, Italy
- Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
- Istituti Fisioterapici Ospitalieri di Roma, Roma, Italy
- +1 more locations on ClinicalTrials.gov
Collaborators
Associazione Italiana Ematologia Oncologia Pediatrica
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04890067 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502885Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer PatientsSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT07193550A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.